CN100375622C - 一种氟尿嘧啶冻干粉针剂及其制备方法 - Google Patents
一种氟尿嘧啶冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN100375622C CN100375622C CNB2003101088257A CN200310108825A CN100375622C CN 100375622 C CN100375622 C CN 100375622C CN B2003101088257 A CNB2003101088257 A CN B2003101088257A CN 200310108825 A CN200310108825 A CN 200310108825A CN 100375622 C CN100375622 C CN 100375622C
- Authority
- CN
- China
- Prior art keywords
- fluorouracil
- hours
- freeze
- lyophilized injectable
- injectable powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 8
- 238000002347 injection Methods 0.000 title abstract description 16
- 239000007924 injection Substances 0.000 title abstract description 16
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title 1
- 229960000684 cytarabine Drugs 0.000 title 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 62
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 61
- 238000001914 filtration Methods 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 16
- 238000000859 sublimation Methods 0.000 claims description 14
- 230000008022 sublimation Effects 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 239000012982 microporous membrane Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001304 Solutol HS 15 Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 13
- 239000000243 solution Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 238000007789 sealing Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 229940090044 injection Drugs 0.000 description 12
- 238000013019 agitation Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940081995 fluorouracil injection Drugs 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WKAXPQAITTYZSG-JFFDMDNDSA-N 1-[(2s,4s,5r)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione;phosphoric acid Chemical compound OP(O)(O)=O.C1[C@H](O)[C@@H](CO)O[C@@]1(F)N1C(=O)NC(=O)C=C1 WKAXPQAITTYZSG-JFFDMDNDSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
项目 | 样品 | 0天 | 5天 | 10天 |
外观及澄明度 | 粉针剂 | 白色疏送块状,加水溶解后得澄明液体 | 白色疏送块状,加水溶解后得澄明液体 | 白色疏送块状,加水溶解后得澄明液体 |
小水针 | 澄明液体 | 澄明液体 | 微黄色澄明液体 | |
含量(%) | 粉针剂 | 100.02 | 99.87 | 99.35 |
小水针 | 99.85 | 96.75 | 94.61 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101088257A CN100375622C (zh) | 2003-11-25 | 2003-11-25 | 一种氟尿嘧啶冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101088257A CN100375622C (zh) | 2003-11-25 | 2003-11-25 | 一种氟尿嘧啶冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1621042A CN1621042A (zh) | 2005-06-01 |
CN100375622C true CN100375622C (zh) | 2008-03-19 |
Family
ID=34758742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101088257A Expired - Fee Related CN100375622C (zh) | 2003-11-25 | 2003-11-25 | 一种氟尿嘧啶冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100375622C (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101239043B (zh) * | 2008-03-07 | 2010-12-08 | 哈尔滨商业大学 | 5-氟尿嘧啶自乳化纳米级冻干粉及其制备方法 |
CN103393688B (zh) * | 2013-08-02 | 2015-03-11 | 海南灵康制药有限公司 | 一种含亚叶酸钙和氟尿嘧啶的药物组合物 |
CN103393685B (zh) * | 2013-08-02 | 2015-01-07 | 海南灵康制药有限公司 | 一种含奥沙利铂和氟尿嘧啶的药物组合物 |
CN108514549B (zh) * | 2018-03-24 | 2020-09-01 | 德州志道医药科技有限公司 | 一种注射用氟尿嘧啶冻干粉及其制备方法 |
CN108272759B (zh) * | 2018-03-24 | 2020-09-04 | 德州志道医药科技有限公司 | 一种氟尿嘧啶注射冻干粉及其制备方法 |
CN108853032B (zh) * | 2018-09-26 | 2019-06-11 | 海南卓泰制药有限公司 | 一种注射用氟尿嘧啶组合物冻干粉剂 |
CN109528664B (zh) * | 2018-12-21 | 2021-07-06 | 江西润泽药业有限公司 | 含乌苯美司-抗肿瘤药物协同前药衍生物的冻干粉剂及其制备方法 |
CN109568276A (zh) * | 2019-01-23 | 2019-04-05 | 海南卓泰制药有限公司 | 一种注射用氟尿嘧啶冻干剂及其制备方法 |
CN110180032A (zh) * | 2019-06-12 | 2019-08-30 | 东华大学 | 一种载药控释的同轴静电纺丝纳米纤维支架及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797388A (en) * | 1984-05-21 | 1989-01-10 | Cetus Corporation | Pharmaceutical compositions with galactitol as carrier |
KR930006430A (ko) * | 1991-09-06 | 1993-04-21 | 천성순 | 카메라를 이용한 3차원 형상의 좌표 측정 방법 및 자동 입력 장치 |
-
2003
- 2003-11-25 CN CNB2003101088257A patent/CN100375622C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797388A (en) * | 1984-05-21 | 1989-01-10 | Cetus Corporation | Pharmaceutical compositions with galactitol as carrier |
KR930006430A (ko) * | 1991-09-06 | 1993-04-21 | 천성순 | 카메라를 이용한 3차원 형상의 좌표 측정 방법 및 자동 입력 장치 |
Non-Patent Citations (1)
Title |
---|
氟尿嘧啶氯化钠注射液生产工艺研究. 张建礼等.中国药业,第18卷第8期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1621042A (zh) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100396276C (zh) | 依普西龙组合物 | |
CN101366696B (zh) | 一种紫杉醇的水溶性注射用药物组合物、制备方法及用途 | |
CN100375622C (zh) | 一种氟尿嘧啶冻干粉针剂及其制备方法 | |
US9993569B2 (en) | Pharmaceutical preparation of camptothecin-containing polymer derivative | |
CN101023940A (zh) | 一种紫杉烷类化合物的药用组合物、制备方法及用途 | |
CN108853032B (zh) | 一种注射用氟尿嘧啶组合物冻干粉剂 | |
CN100586422C (zh) | 比伐卢定冻干粉针剂及其制备方法 | |
CN102614118B (zh) | 注射用盐酸表柔比星制剂的制备方法及制剂 | |
CN100522173C (zh) | 含有培美曲塞的药物组合物 | |
KR20170015507A (ko) | 암을 치료하는 조성물 및 방법 | |
CN104667289A (zh) | 一种抗肿瘤药物载体及其使用方法 | |
CN101485652B (zh) | 一种紫杉烷类化合物的组合物、其制备方法和用途 | |
CN103735514A (zh) | 一种聚乙二醇维生素e琥珀酸酯和钙网蛋白修饰的纳米粒及其制备方法 | |
Zhang et al. | Programmable DNA hydrogel assisting microcrystal formulations for sustained Locoregional drug delivery in surgical residual tumor lesions and lymph node metastasis | |
CN103610639A (zh) | 含缓冲盐的聚合物胶束载药组合物及其制备方法 | |
EP4223300A1 (en) | Use of probiotic component and pharmaceutical composition containing probiotic component | |
CN103720666B (zh) | 一种注射用硼替佐米冻干制剂的制备方法 | |
CN107921040A (zh) | 含有喜树碱类高分子衍生物的药物组合物 | |
CN110063962A (zh) | 一种氯法拉滨甲氨蝶呤双药制剂及其制备方法 | |
CN100594889C (zh) | 一种喷昔洛韦冻干粉针剂及其制备方法 | |
CN103393685B (zh) | 一种含奥沙利铂和氟尿嘧啶的药物组合物 | |
CN103690494B (zh) | 一种低杂质含有奥沙利铂的组合物及其制备方法 | |
CN103393688B (zh) | 一种含亚叶酸钙和氟尿嘧啶的药物组合物 | |
WO2023050297A1 (zh) | 一种局部药物组合物、应用及试剂盒 | |
CN107837237B (zh) | 一种培美曲塞二钠药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN POLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20100707 Owner name: ZHEJIANG RUIDA PHARMACEUTICAL CO., LTD. HANGZHOU S |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310004 HOUSE 5, BUILDING 9, NO.167, HUANCHENG NORTH ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 571127 GUILINYANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, MEILAN DISTRICT, HAIKOU CITY, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100707 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Co-patentee after: Zhejiang Ruida Pharmaceutical Co.,Ltd. Patentee after: Hainan Poly Pharm Co.,Ltd. Co-patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 5, building 9, building 167, building 310004, Ring North Road, Hangzhou, Zhejiang Patentee before: Fan Minhua |
|
CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Hainan Puli Pharmaceutical Co., Ltd.|571127. Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Province|Zhejiang Ruida Pharmaceutical Co. Ltd.|Hangzhou seily Pharmaceutical Research Institute Co Ltd False: Hainan Puli Pharmaceutical Co., Ltd.|571127. Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Province|Zhejiang Ruida Pharmaceutical Co. Ltd.|Hangzhou seily Pharmaceutical Research Institute Co Ltd Number: 33 Volume: 26 |
|
CI03 | Correction of invention patent |
Correction item: Patentee Correct: Zhejiang Ridae Pharmaceutical Co., Ltd. False: Zhejiang Ruida Pharmaceutical Co., Ltd. Number: 33 Page: The title page Volume: 26 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080319 Termination date: 20131125 |
|
C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: Zhejiang Ruida Pharm Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |